Iteos Therapeutics — Investor Presentation (January 2023)
18 slides from Iteos Therapeutics's investor presentation, Jan 9, 2023

Slide 1: Better Immunotherapies to Improve the Lives of People with Cancer
Better Immunotherapies to Improve the Lives of People with Cancer iteostherapeutics.com

Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements. Any statements that are not solely statements of historical fact are forward-looking statements. Words such as “believe,” “anticipate,” “plan,” “expect,” “will,” “may,” “intend,” “prepare,” “look,” “potential,” “possib

Slide 3: Better Immunotherapies to Improve the Lives of People with Cancer
Better Immunotherapies to Improve the Lives of People with Cancer iteostherapeutics.com

Slide 4: iTeos well positioned to deliver better drugs to patients
iTeos well positioned to deliver better drugs to patients 3 11 Clinical drug Clinical studies planned or ongoing $ 752 M* Cash balance to fund development into 2026 68K candidates Patients diagnosed each year in US for indications in 2023 currently in development $ 2B Partnership with unique develop

Slide 5: We build better drugs for people with cancer
We build better drugs for people with cancer EOS-448: Inupadenant & EOS-984: Anti-TIGIT optimized for Designed to fully exploit immune cell activation the adenosine pathway Expansive and unique development Leverage deep understanding of the plan with GSK adenosine pathway with a focused clinical pla

Slide 6: Expansive and differentiated development pipeline expected to make significant progress over 2023
Expansive and differentiated development pipeline expected to make significant progress over 2023 Discovery Preclinical Phase 1 Phase 2 Phase 3 EOS-448: IgG1 antibody targeting TIGIT + dostarlimab | 1L NSCLC PDLI high * + dostarlimab | 1L NSCLC PDL1high + dostarlimab | 1L HNSCC PDL1high/low + dostar

Slide 7: EOS-448 / GSK4428859A
EOS-448 / GSK4428859A iteostherapeutics.com 7

Slide 8: iTeos ideally positioned entering a defining year for TIGIT
iTeos ideally positioned entering a defining year for TIGIT Why Validated target in two randomized trials with broad potential. TIGIT Why Antibody optimized to activate multiple types of immune cells. EOS-448 Why $2B collaboration enabling a differentiated and expansive clinical iTeos & GSK developm

Slide 9: Anti-TIGIT antibody with best-in-class properties and active Fc
Anti-TIGIT antibody with best-in-class properties and active Fc to induce multiple types of immune response Antibody design translates to Maximize activity by leveraging Antibody design translates reduction in immunosuppressive both ends of antibody into preclinical differentiation cells in patient

Slide 10: GSK's PD-1 dostarlimab is the ideal combination partner for EOS-448
GSK’s PD-1 dostarlimab is the ideal combination partner for EOS-448 Dostarlimab has proven activity in lung, rectal and endometrial cancers Dostarlimab demonstrated compelling efficacy profile in head-to-head trial compared to Pembrolizumab Dostarlimab + CT Pembrolizumab + CT PERLA Study (PFS data a

Slide 11: First wave of development underway in large indications
First wave of development underway in large indications EOS-448: IgG1 antibody targeting TIGIT U.S. annual incidence Discovery Preclinical Phase 1 Phase 2 Phase 3 Relapsed Refractory + dostarlimab | 1L NSCLC PDLI high * MM 1L NSCLC + dostarlimab | 1L NSCLC PDL1high PD-L1 High 56 K + dostarlimab | 1L

Slide 12: Adenosine pathway
Adenosine pathway iteostherapeutics.com 12

Slide 13: Leveraging unique understanding of adenosine pathway to realize full potential
Leveraging unique understanding of adenosine pathway to realize full potential Why Major mechanism of immunosuppression with recent clinical Adenosine validation. Pathway Why Uniquely designed for activity in solid tumors. Inupadenant Why Deep understanding of the adenosine pathway leading to iTeos

Slide 14: Best-in-Class profile: Inupadenant optimized for activity at high adenosine concentration
Best-in-Class profile: Inupadenant optimized for activity at high adenosine concentration found in tumors Very high concentrations of Insurmountable, highly selective adenosine in multiple tumor types A2AR antagonist High 400 iTeos Adenosine (μM) Arcus Potency (IC50:nM 300 Corvus AstraZeneca Novarti

Slide 15: Clinical activity indicates potential of iTeos-discovered biomarker to guide patient selection
Clinical activity indicates potential of iTeos-discovered biomarker to guide patient selection RECIST-evaluable patients (N=38) Biomarker case study *Progression-Free >6 Months Ongoing partial response with inupadenant monotherapy in patient with highest biomarker level observed to date Tumor: Adeno

Slide 16: Leveraging our unique knowledge of adenosine pathway with focused investment
Leveraging our unique knowledge of adenosine pathway with focused investment Discovery Preclinical Phase 1 Phase 2 Phase 3 Inupadenant: Small molecule targeting A2A receptor Monotherapy | High Biomarker + pembrolizumab | PD-1 Resistant Melanoma + chemotherapy | Post-IO Chemo-naïve NSCLC EOS-984: Sma

Slide 17: iTeos' Mission: We Build Better Drugs
iTeos’ Mission: We Build Better Drugs 2023 Outlook: • Pivotal year for TIGIT • EOS-448: Optimized active TIGIT antibody with unique development plans • Inupadenant & EOS-984: Designed to exploit the adenosine pathway iteostherapeutics.com 17

Slide 18: Thank You
Thank You iteostherapeutics.com 18
Source: SEC EDGAR · 8-K filed Jan 9, 2023
More decks from Iteos Therapeutics Inc
JPM HC Conference January 202529 slides · Jan 13, 2025
ESMO 202420 slides · Sep 16, 2024
Investor Presentation (January 2024)27 slides · Jan 10, 2024
Investor Presentation (January 2022)12 slides · Jan 11, 2022
Corporate Update (April 2021)19 slides · Apr 12, 2021
Investor Presentation (January 2021)16 slides · Jan 11, 2021